/OCS
OCS Stock - Oculis Holding AG
Healthcare|BiotechnologyNASDAQ
$21.25+9.09%
+$1.77 (+9.09%) • Dec 19
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.78
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+99.2%upside
Target: $42.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OCS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.04 – $21.46
TARGET (TP)$42.33
STOP LOSS$19.55
RISK/REWARD1:12.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.14
52W High$23.08
52W Low$14.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $686,000 | N/A | N/A | N/A | N/A |
| Gross Profit | $-51,397,000 | N/A | N/A | N/A | N/A |
| Gross Margin | -7492.3% | N/A | N/A | N/A | N/A |
| Operating Income | $-73,204,000 | $-80,714,000 | $-32,376,000 | $-13,232,000 | $-12,336,000 |
| Net Income | $-85,777,000 | $-88,802,000 | $-38,698,000 | $-18,552,000 | $-14,873,000 |
| Net Margin | -12503.9% | N/A | N/A | N/A | N/A |
| EPS | $-2.12 | $-2.97 | $-1.18 | $-0.57 | $-0.45 |
Company Overview
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish0 Neutral/Bearish
Price Targets
$33
Average Target
↑ 55.3% Upside
Now
$22
Low
$33
Average
$58
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 19th 2025 | JP Morgan | Initiation | Overweight | $38 |
| August 27th 2025 | Needham | Initiation | Buy | $36 |
| December 5th 2023 | Chardan Capital Markets | Initiation | Buy | $30 |
| October 5th 2023 | Stifel | Initiation | Buy | $35 |
| June 14th 2023 | BofA Securities | Initiation | Buy | $22 |
| June 12th 2023 | H.C. Wainwright | Initiation | Buy | $28 |
| June 8th 2023 | Robert W. Baird | Initiation | Outperform | $58 |
| May 10th 2023 | Pareto | Initiation | Buy | $23 |
| April 28th 2023 | Wedbush | Initiation | Outperform | $27 |
Earnings History & Surprises
OCSBeat Rate
20%
Last 10 quarters
Avg Surprise
-15.5%
EPS vs Estimate
Beats / Misses
2/8
Last 12 quarters
Latest EPS
$-0.40
Q4 2025
EPS Surprise History
Q1 24
+9.5%
$-0.38vs$-0.42
Q2 24
-7.3%
$-0.44vs$-0.41
Q3 24
-30.2%
$-0.56vs$-0.43
Q4 24
-5.8%
$-0.55vs$-0.52
Q1 25
-58.3%
$-0.76vs$-0.48
Q2 25
-51.0%
$-0.77vs$-0.51
Q3 25
-11.3%
$-0.59vs$-0.53
Q4 25
+20.0%
$-0.40vs$-0.50
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 10, 2026 | $-0.43 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.50 | $-0.40 | +20.0% | ✓ BEAT |
Q3 2025 | Aug 21, 2025 | $-0.53 | $-0.59 | -11.3% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.51 | $-0.77 | -51.0% | ✗ MISS |
Q1 2025 | Mar 11, 2025 | $-0.48 | $-0.76 | -58.3% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.52 | $-0.55 | -5.8% | ✗ MISS |
Q3 2024 | Aug 27, 2024 | $-0.43 | $-0.56 | -30.2% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.41 | $-0.44 | -7.3% | ✗ MISS |
Q1 2024 | Mar 18, 2024 | $-0.42 | $-0.38 | +9.5% | ✓ BEAT |
Q4 2023 | Nov 15, 2023 | $-0.36 | $-0.38 | -5.6% | ✗ MISS |
Q3 2023 | Aug 29, 2023 | $-0.33 | $-0.38 | -15.2% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | — | $-1.51 | — | — |
Q1 2023 | Mar 28, 2023 | — | $-0.30 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.31 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.39 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.32 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.19 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.16 | — | — |
Latest News
JP Morgan Initiates Coverage On Oculis Holding with Overweight Rating, Announces Price Target of $38
📈 PositiveBenzinga•Dec 19, 2025, 12:53 PM
LifeSci Capital Initiates Coverage On Oculis Holding with Outperform Rating, Announces Price Target of $55
📈 PositiveBenzinga•Dec 3, 2025, 01:55 PM
B of A Securities Maintains Buy on Oculis Holding, Lowers Price Target to $29
➖ NeutralBenzinga•Nov 13, 2025, 05:43 PM
Chardan Capital Maintains Buy on Oculis Holding, Maintains $51 Price Target
📈 PositiveBenzinga•Nov 11, 2025, 01:09 PM
HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $42
📈 PositiveBenzinga•Nov 11, 2025, 12:55 PM
Needham Reiterates Buy on Oculis Holding, Maintains $36 Price Target
📈 PositiveBenzinga•Nov 11, 2025, 11:04 AM
CORRECTION: Oculis Holding Q3 EPS $(0.40) Beats $(0.50) Estimate, Sales $303.761K Beat $250.000K Estimate
📈 PositiveBenzinga•Nov 10, 2025, 11:41 PM
Oculis Holding Q3 EPS $(0.32) Beats $(0.50) Estimate, Sales $243.000K Miss $250.000K Estimate
📈 PositiveBenzinga•Nov 10, 2025, 09:45 PM
Oculis Raises $110M Through Oversubscribed Offering To Advance Privosegtor Clinical Development And Strengthen Ophthalmology Pipeline
📈 PositiveBenzinga•Oct 30, 2025, 08:33 AM
Oculis To Highlight Late-Stage Ophthalmic Pipeline At Eyecelerator And AAO 2025 With Privosegtor And OCS-01 Updates
📈 PositiveBenzinga•Oct 14, 2025, 08:14 AM
Chardan Capital Maintains Buy on Oculis Holding, Raises Price Target to $51
📈 PositiveBenzinga•Oct 8, 2025, 11:19 AM
HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $36
📈 PositiveBenzinga•Oct 7, 2025, 10:49 AM
Oculis Advances Privosegtor Into FDA-Backed Pivotal Trials, Aiming To Deliver First Neuroprotective Therapy For Vision Loss
📈 PositiveBenzinga•Oct 6, 2025, 08:10 AM
Oculis Reports Trial Results Showing Vision Gains In Patients With Acute Optic Neuritis
📈 PositiveBenzinga•Sep 22, 2025, 08:32 AM
Reported Sunday, Oculis Announces Expanded Data Analysis Of OCS-01 Eye Drops In DME Subgroups From Phase 3 DIAMOND Program At EURETINA
📈 PositiveBenzinga•Sep 2, 2025, 07:17 AM
Needham Initiates Coverage On Oculis Holding with Buy Rating, Announces Price Target of $36
📈 PositiveBenzinga•Aug 27, 2025, 12:17 PM
HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $33
📈 PositiveBenzinga•Aug 22, 2025, 10:46 AM
Oculis Holding Q2 EPS $(0.57) Misses $(0.53) Estimate, Sales $307.417K Beat $250.000K Estimate
➖ NeutralBenzinga•Aug 21, 2025, 08:15 PM
Frequently Asked Questions about OCS
What is OCS's current stock price?
Oculis Holding AG (OCS) is currently trading at $21.25 per share. The stock has moved +9.09% today.
What is the analyst price target for OCS?
The average analyst price target for OCS is $42.33, based on 1 analyst.
What sector is Oculis Holding AG in?
Oculis Holding AG operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is OCS's market cap?
Oculis Holding AG has a market capitalization of $1.11 billion, making it a small-cap company.
Does OCS pay dividends?
No, Oculis Holding AG does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$49.08
Mkt Cap: $1.4B
BBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
MNMD
Mind Medicine (MindMed) Inc.
$12.70
Mkt Cap: $1.0B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
SANA
Sana Biotechnology, Inc.
$4.36
Mkt Cap: $1.2B
URGN
UroGen Pharma Ltd.
$22.80
Mkt Cap: $1.1B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to OCS for comparison